The gene expression profile of extraskeletal myxoid chondrosarcoma

Journal of Pathology

Volumn 206, Issue 4, 2005, Pages 433-444

  Subramanian, Subbaya ^a   West, Robert B ^a   Marinelli, Robert J ^b   Nielsen, Torsten O ^c   Rubin, Brian P ^d   Goldblum, John R ^e   Patel, Rajiv M ^e   Zhu, Shirley ^a   Montgomery, Kelli ^a   Ng, Tony L ^c   Corless, Christopher L ^f   Heinrich, Michael C ^f   van de Rijn, Matt ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Expressing profile; Extraskeletal myxoid chondrosarcoma; Lipid metabolism; Neuromedin B gene; Tissue microarray

Indexed keywords

CHLORIDE CHANNEL; COMPLEMENTARY DNA; LIPID; MEMBRANE PROTEIN; NEUROMEDIN B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; CANCER SURVIVAL; CHONDROSARCOMA; CHROMOSOME 22Q; CHROMOSOME 9Q; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DNA MICROARRAY; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; LIPID METABOLISM; MALE; MORPHOLOGY; PRIORITY JOURNAL; REVIEW; SARCOMA; SOFT TISSUE TUMOR; TISSUE MICROARRAY;

ADULT; AGED; CELL DIFFERENTIATION; CELL DIVISION; CHONDROSARCOMA; CLUSTER ANALYSIS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; MALE; MICROTUBULES; MIDDLE AGED; NEOPLASM PROTEINS; NEUROKININ B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 22644447659     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1792     Document Type: Review

References (97)

1. Enzinger FM, Shiraki M. Extraskeletal myxoid chondrosarcoma. An analysis of 34 cases. Hum Pathol 1972;3:421-435.
2. Klijanienko J, Micheau C, Cote R, Flamant F, Caillaud JM. Unusual extraskeletal myxoid chondrosarcoma in a child. Histopathology 1990;16:196-198.
3. Greenspan A, Unni KK, Blake L, Rab G. Extraskeletal myxoid chondrosarcoma: an unusual tumour in a 6-year-old boy. Can Assoc Radiol J 1994;45:62-65.
4. Stenman G, Andersson H, Mandahl N, Meis-Kindblom JM, Kindblom LG. Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. Int J Cancer 1995; 62:398-402.
5. Sciot R, Dal Cin P, Fletcher C, et al. t(9;22)(q22-31;q11-12) is a consistent marker of extraskeletal myxoid chondrosarcoma: evaluation of three cases. Mod Pathol 1995; 8:765-768.
6. Labelle Y, Bussieres J, Courjal F, Goldring MB. The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator. Oncogene 1999;18:3303-3308.
7. Ohkura N, Yaguchi H, Tsukada T, Yamaguchi K. The EWS/NOR1 fusion gene product gains a novel activity affecting pre-mRNA splicing. J Biol Chem 2002;277:535-543.
8. Sjogren H, Meis-Kindblom J, Kindblom LG, Aman P, Stenman G. Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma. Cancer Res 1999;59:5064-5067.
9. Attwooll C, Tariq M, Harris M, et al. Identification of a novel fusion gene involving hTAFII68 and CHN from a t(9;17)(q22;q11.2) translocation in an extraskeletal myxoid chondrosarcoma. Oncogene 1999;18:7599-7601.
10. Hisaoka M, Ishida T, Imamura T, Hashimoto H. TFG is a novel fusion partner of NOR1 in extraskeletal myxoid chondrosarcoma. Genes Chromosomes Cancer 2004;40:325-328.
11. Harris M, Coyne J, Tariq M, et al. Extraskeletal myxoid chondrosarcoma with neuroendocrine differentiation: a pathologic, cytogenetic, and molecular study of a case with a novel translocation t(9;17)(q22;q11.2). Am J Surg Pathol 2000;24:1020-1026.
12. Goh YW, Spagnolo DV, Platten M, et al. Extraskeletal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immuno-ultrastructural study indicating neuroendocrine differentiation. Histopathology 2001; 39:514-524.
13. Okamoto S, Hisaoka M, Ishida T, et al. Extraskeletal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 18 cases. Hum Pathol 2001; 32:1116-1124.
14. Domanski HA, Carlen B, Mertens F, Akerman M. Extraskeletal myxoid chondrosarcoma with neuroendocrine differentiation: a case report with fine-needle aspiration biopsy, histopathology, electron microscopy, and cytogenetics. Ultrastruct Pathol 2003;27:363-368.
15. Sjogren H, Meis-Kindblom JM, Orndal C, et al. Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma - cytogenetic, molecular genetic, and cDNA microarray analyses. Am J Pathol 2003;162:781-792.
16. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002;359:1301-1307.
17. Linn SC, West RB, Pollack JR, et al. Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 2003;163:2383-2395.
18. Subramanian S, West RB, Corless CL, et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 2004; 23:7780-7790.
19. Peron CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
20. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14 863 -14 868.
21. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-5121.
22. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004; 165:107-113.
23. West RB, Harvell J, Linn SC, et al. Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol 2004;28:1063-1069.
24. Ng TL, Gown AM, BarTy TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005;18:68-74.
25. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000; 289:1197-1202.
26. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 2002;160:91-99.
27. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 2002; 161:1557-1565.
28. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-1572.
29. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
30. Puigserver P, Adelmant G, Wu Z, et al. Activation of PPARgamma coactivator-1 through transcription factor docking. Science 1999;286:1368-1371.
31. Rosen ED, Hsu CH, Wang X, et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev 2002;16:22-26.
32. Li AC, Glass CK. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 2004;45:2161-2173.
33. Rosen ED, Kulkarni RN, Sarraf P, et al. Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 2003;23:7222-7229.
34. Park KS, Lee RD, Kang SK, et al. Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway. Exp Cell Res 2004;297:424-433.
35. Kodera Y, Takeyama K, Murayama A, et al. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J Biol Chem 2000; 275:33 201-33 204.
36. Prockop DJ, Gregory CA, Spees JL. One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci U S A 2003;100(Suppl 1): 11 917-11 923.
37. Hoang BH, Kubo T, Healey JH, et al. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004; 109:106-111.
38. Zimmermann DR, Ruoslahti E. Multiple domains of the large fibroblast proteoglycan, versican. EMBO J 1989;8:2975-2981.
39. Naso MF, Zimmermann DR, Iozzo RV. Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. J Biol Chem 1994;269:32 999-33 008.
40. Yoon H, Liyanarachchi S, Wright FA, et al. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci U S A 2002; 99:15 632-15 637.
41. Hayashita-Kinoh H, Kinoh H, Okada A, et al. Membrane-type 5 matrix metalloproteinase is expressed in differentiated neurons and regulates axonal growth. Cell Growth Differ 2001; 12:573-580.
42. Fletcher CD, Powell G, McKee PH. Extraskeletal myxoid chondrosarcoma: a histochemical and immunohistochemical study. Histopathology 1986;10:489-499.
43. Wu Y, Sheng W, Chen L, et al. Versican V1 isoform induces neuronal differentiation and promotes neurite outgrowth. Mol Biol Cell 2004;15:2093-2104.
44. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002;117:188-193.
45. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
46. Lan MS, Russell EK, Lu J, Johnson BE, Notkins AL. IA-1, a new marker for neuroendocrine differentiation in human lung cancer cell lines. Cancer Res 1993;53:4169-4171.
47. Clegg N, Ferguson C, True LD, et al. Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 2003;55:55-64.
48. Chejfec G, Falkmer S, Grimelius L, et al. Synaptophysin. A new marker for pancreatic neuroendocrine tumors. Am J Surg Pathol 1987;11:241-247.
49. Gaetano C, Manni I, Bossi G, et al. Retinoic, acid and cAMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells. Eur J Cancer 1995; 31A:447-452.
50. Sansal I, Dupont E, Toru D, Evrard C, Rouget P. NPDC-1, a regulator of neural cell proliferation and differentiation, interacts with E2F-1, reduces its binding to DNA and modulates its transcriptional activity. Oncogene 2000;19:5000-5009.
51. Nichols NR. Ndrg2, a novel gene regulated by adrenal steroids and antidepressants, is highly expressed in astrocytes. Ann N Y Acad Sci 2003;1007:349-356.
52. Borsani G, Rugarli EI, Taglialatela M, Wong C, Ballabio A. Characterization of a human and murine gene (CLCN3) sharing similarities to voltage-gated chloride channels and to a yeast integral membrane protein. Genomics 1995;27:131-141.
53. Gomes I, Xiong W, Miki T, Rosner MR. A proline- and glutamine-rich protein promotes apoptosis in neuronal cells. J Neurochem 1999;73:612-622.
54. Medina M, Marinescu RC, Overhauser J, Kosik KS. Hemizygosity of delta-catenin (CTNND2) is associated with severe mental retardation in cri-du-chat syndrome. Genomics 2000;63:157-164.
55. Naeve GS, Ramakrishnan M, Kramer R, et al. Neuritin: a gene induced by neural activity and neurotrophins that promotes neuritogenesis. Proc Natl Acad Sci U S A 1997;94:2648-2653.
56. Yokoyama M, Nishi Y, Yoshii J, Okubo K, Matsubara K. Identification and cloning of neuroblastoma-specific and nerve tissue-specific genes through compiled expression profiles. DNA Res 1996;3:311-320.
57. Ouafik LH, Stoffers DA, Campbell TA, et al. The multifunctional peptidylglycine alpha-amidating monooxygenase gene: exon/intron organization of catalytic, processing, and routing domains. Mol Endocrinol 1992;6:1571-1584.
58. Taguchi A, Wanaka A, Mori T, et al. Molecular cloning of novel leucine-rich repeat proteins and their expression in the developing mouse nervous system. Brain Res Mol Brain Res 1996; 35:31-40.
59. Formstone CJ, Little PF. The flamingo-related mouse Celsr family (Celsr1-3) genes exhibit distinct patterns of expression during embryonic development. Mech Dev 2001;109:91-94.
60. Cremona O, Di Paolo G, Wenk MR, et al. Essential role of phosphoinositide metabolism in synaptic vesicle recycling. Cell 1999;99:179-188.
61. Eiraku M, Hirata Y, Takeshima H, Hirano T, Kengaku M. Delta/notch-like epidermal growth factor (EGF)-related receptor, a novel EGF-like repeat-containing protein targeted to dendrites of developing and adult central nervous system neurons. J Biol Chem 2002; 277:25 400-25 407.
62. Xu T, Bianco P, Fisher LW, et al. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nature Genet 1998;20:78-82.
63. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett 1994; 345:27-32.
64. Jiang Y, Liu YE, Goldberg ID, Shi YE. Gamma synuclein, a novel heat-shock protein-associated chaperone, stimulates ligand-dependent estrogen receptor alpha signaling and mammary tumorigenesis. Cancer Res 2004;64:4539-4546.
65. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003;300:636-640.
66. Ninkina NN, Alimova-Kost MV, Paterson JW, et al. Organization, expression and polymorphism of the human persyn gene. Hum Mol Genet 1998;7:1417-1424.
67. Crean JK, Furlong F, Finlay D, et al. Connective tissue growth factor [CTGF]/CCN2 stimulates mesangial cell migration through integrated dissolution of focal adhesion complexes and activation of cell polarization. FASEB J 2004;18:1541-1543.
68. Zemni R, Bienvenu T, Vinet MC, et al. A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation. Nature Genet 2000;24:167-170.
69. Chen J, Larochelle S, Li X, Suter B. Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature 2003;424:228-232.
70. Abe MK, Saelzler MP, Espinosa R 3rd, et al. ERK8, a new member of the mitogen-activated protein kinase family. J Biol Chem 2002;277:16 733-16 743.
71. Insabato L, Terracciano LM, Boscaino A, et al. Extraskeletal myxoid chondrosarcoma with intranuclear vacuoles and microtubular aggregates in the rough endoplasmic reticulum. Report of a case with fine needle aspiration and electron microscopy. Acta Cytol 1990;34:858-862.
72. Hisaoka M, Okamoto S, Koyama S, et al. Microtubule-associated protein-2 and class III beta-tubulin are expressed in extraskeletal myxoid chondrosarcoma. Mod Pathol 2003; 16:453-459.
73. Devred F, Barbier P, Douillard S, et al. Tau induces ring and microtubule formation from alpha beta-tubulin dimers under nonassembly conditions. Biochemistry 2004;43:10 520-10 531.
74. Hu B, McPhaul L, Cornford M, et al. Expression of tau proteins and tubulin in extraskeletal myxoid chondrosarcoma, chordoma, and other chondroid tumors. Am J Clin Pathol 1999; 112:189-193.
75. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 2004;380:651-659.
76. Labelle Y, Zucman J, Stenman G, et al. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum Mol Genet 1995;4:2219-2226.
77. Fukuma M, Okita H, Hata J, Umezawa A. Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene 2003;22:1-9.
78. Bailly RA, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994;14:3230-3241.
79. Ito E, Honma R, Imai J, et al. A tetraspanin-family protein, T-cell acute lymphoblastic leukemia-associated antigen 1, is induced by the Ewing's sarcoma-Wilms' tumor 1 fusion protein of desmoplastic small round-cell tumor. Am J Pathol 2003; 163:2165-2172.
80. Ohki-Hamazaki H. Neuromedin B. Prog Neurobiol 2000; 62: 297-312.
81. Cardona C, Rabbitts PH, Spindel ER, et al. Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines. Cancer Res 1991;51:5205-5211.
82. Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 2003;27(Suppl 3):S17-S21.
83. Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 2002;59:790-798.
84. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997;94:4318-4323.
85. Dreyer C, Krey G, Keller H, et al. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992;68:879-887.
86. Devchand PR, Ijpenberg A, Devesvergne B, Wahli W. PPARs: nuclear receptors for fatty acids, eicosanoids, and xenobiotics. Adv Exp Med Biol 1999;469:231-236.
87. Rusyn I, Rose ML, Bojes HK, Thurman RG. Novel role of oxidants in the molecular mechanism of action of peroxisome proliferators. Antioxid Redox Signal 2000;2:607-621.
88. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
89. Gupta RA, Brockman JA, Sarraf P, Willson TM, DuBois RN. Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem 2001;276:29 681-29 687.
90. Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 1997;94:237-241.
91. Lee CH, Evans RM. Peroxisome proliferator-activated receptor-gamma in macrophage lipid homeostasis. Trends Endocrinol Metab 2002;13:331-335.
92. Llaverias G, Vazquez-Carrera M, Sanchez RM, et al. Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J Lipid Res 2004;45:2015-2024.
93. Leesnitzer LM, Parks DJ, Bledsoe RK, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002;41:6640-6650.
94. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43:527-550.
95. Koyama H, Boueres JK, Han W, et al. 5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists. Bioorg Med Chem Lett 2003;13:1801-1804.
96. Slomiany BL, Slomiany A. Role of epidermal growth factor receptor transactivation in PPARgamma-dependent suppression of Helicobacter pylori interference with gastric mucin synthesis. Inflammopharmacology 2004;12:177-188.
97. Liu DC, Zang CB, Liu HY, et al. A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells. Acta Pharmacol Sin 2004; 25:1312-1319.